Representative Brian Bilbray (R-CA) introduced a bill to the US House that would prevent states from requiring inspections of drug or device manufacturers, packagers, or distributors that are duplicative to inspections required by FDA. The Science and Technology Regulatory Relief...

Published in the February 2008 Oregon State Board of Pharmacy Newsletter The Board’s inspectors continue to encounter interesting situations during their on-site pharmacy inspections. One of the routine checks on the inspectors’ lists is the refrigerator/freezer or other controlled temperature...

Published in the December 2007 Vermont Board of Pharmacy Newsletter Following an inspection of a facility, a letter is sent to the attention of the pharmacist manager noting any discrepancies found. The Board has noticed an increase in responses from corporate...

Published in the May 2007 Missouri Board of Pharmacy Newsletter Inspectors are routinely asked for a list of the most common deficiencies noted during inspections. Below is a list of those that result in compliance notices being issued during inspections:...

Reprinted from the January 2007 Nevada State Board of Pharmacy Newsletter. Proper canceling of Schedule II prescriptions: NAC 453.450(3) reads “Each prescription for a controlled substance listed in [S]chedule II must, immediately after filling, be conspicuously cancelled on its face....

Reprinted from the October 2006 Minnesota Board of Pharmacy Newsletter. By Bill Sybrant, Board Inspector A completed on-site inspection is not a guaranteed stamp of approval that a site is 100% compliant. During routine inspection, which can last anywhere from...

Published in the October 2006 Oklahoma State Board of Pharmacy Newsletter Pseudoephedrine (PSE) Training: As of September 30, 2006, retailers must train their employees on the new PSE restrictions using Drug Enforcement Administration (DEA) materials. Go to www.deadiversion.usdoj.gov/meth/trg_retail_081106.pdf. Reporting PSE...